Replimune Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Replimune Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($247.30M) | May 22, 2025 |
| FY2025 | Mar 31, 2024 | ($215.79M) | May 22, 2025 |
| FY2024 | Mar 31, 2023 | ($174.28M) | May 16, 2024 |
| FY2023 | Mar 31, 2022 | ($118.04M) | May 18, 2023 |
| FY2021 | Mar 31, 2021 | ($21.50M) | May 20, 2021 |
| FY2021 | Dec 31, 2020 | ($21.78M) | May 20, 2021 |
| FY2021 | Sep 30, 2020 | ($20.10M) | May 20, 2021 |
| FY2021 | Jun 30, 2020 | ($17.49M) | May 20, 2021 |
| FY2021 | Mar 31, 2020 | ($15.79M) | May 20, 2021 |
| FY2021 | Dec 31, 2019 | ($16.19M) | May 20, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($261.63M) | May 22, 2025 |
| FY2025 | Mar 31, 2024 | ($234.77M) | May 22, 2025 |
| FY2024 | Mar 31, 2023 | ($177.08M) | May 16, 2024 |
| FY2023 | Mar 31, 2022 | ($118.31M) | May 18, 2023 |
| FY2022 | Mar 31, 2021 | ($79.96M) | May 19, 2022 |
| FY2021 | Mar 31, 2020 | ($56.20M) | May 20, 2021 |
| FY2019 | Mar 31, 2019 | ($30.95M) | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | ($19.23M) | Jun 3, 2020 |
| FY2019 | Mar 31, 2017 | ($9.65M) | Jun 28, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $189.45M | May 22, 2025 |
| FY2025 | Mar 31, 2024 | $174.96M | May 22, 2025 |
| FY2024 | Mar 31, 2023 | $126.53M | May 16, 2024 |
| FY2023 | Mar 31, 2022 | $79.55M | May 18, 2023 |
| FY2022 | Mar 31, 2021 | $56.75M | May 19, 2022 |
| FY2021 | Mar 31, 2020 | $38.76M | May 20, 2021 |
| FY2019 | Mar 31, 2019 | $22.17M | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | $13.52M | Jun 3, 2020 |
| FY2019 | Mar 31, 2017 | $6.94M | Jun 28, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($192.25M) | May 22, 2025 |
| FY2025 | Mar 31, 2024 | ($185.47M) | May 22, 2025 |
| FY2024 | Mar 31, 2023 | ($128.05M) | May 16, 2024 |
| FY2023 | Mar 31, 2022 | ($82.18M) | May 18, 2023 |
| FY2022 | Mar 31, 2021 | ($61.39M) | May 19, 2022 |
| FY2021 | Mar 31, 2020 | ($60.55M) | May 20, 2021 |
| FY2019 | Mar 31, 2019 | ($25.38M) | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | ($16.01M) | Jun 3, 2020 |
| FY2019 | Mar 31, 2017 | ($7.08M) | Jun 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $2.27M | May 18, 2023 |
| FY2023 | Mar 31, 2022 | $2.34M | May 18, 2023 |
| FY2022 | Mar 31, 2021 | $2.39M | May 19, 2022 |
| FY2021 | Mar 31, 2020 | $6.54M | May 20, 2021 |
| FY2019 | Mar 31, 2019 | $2.60M | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | $136.0K | Jun 3, 2020 |
| FY2019 | Mar 31, 2017 | $238.0K | Jun 28, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $551.33M | May 22, 2025 |
| FY2025 | Mar 31, 2024 | $487.72M | May 22, 2025 |
| FY2024 | Mar 31, 2023 | $646.59M | May 16, 2024 |
| FY2023 | Mar 31, 2022 | $461.19M | May 18, 2023 |
| FY2022 | Mar 31, 2021 | $543.10M | May 19, 2022 |
| FY2021 | Mar 31, 2020 | $234.10M | May 20, 2021 |
| FY2019 | Mar 31, 2019 | $154.33M | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | $65.15M | Jun 28, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $135.49M | May 22, 2025 |
| FY2025 | Mar 31, 2024 | $113.21M | May 22, 2025 |
| FY2024 | Mar 31, 2023 | $91.30M | May 16, 2024 |
| FY2023 | Mar 31, 2022 | $49.96M | May 18, 2023 |
| FY2022 | Mar 31, 2021 | $44.37M | May 19, 2022 |
| FY2021 | Mar 31, 2020 | $50.38M | May 20, 2021 |
| FY2019 | Mar 31, 2019 | $16.47M | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | $6.86M | Jun 28, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $415.84M | May 22, 2025 |
| FY2025 | Mar 31, 2024 | $374.51M | May 22, 2025 |
| FY2025 | Mar 31, 2023 | $555.29M | May 22, 2025 |
| FY2024 | Mar 31, 2022 | $411.23M | May 16, 2024 |
| FY2023 | Mar 31, 2021 | $498.73M | May 18, 2023 |
| FY2022 | Mar 31, 2020 | $183.72M | May 19, 2022 |
| FY2021 | Mar 31, 2019 | $137.86M | May 20, 2021 |
| FY2019 | Mar 31, 2018 | ($28.07M) | Jun 3, 2020 |
| FY2019 | Mar 31, 2017 | ($11.52M) | Jun 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($948.58M) | May 22, 2025 |
| FY2025 | Mar 31, 2024 | ($701.28M) | May 22, 2025 |
| FY2024 | Mar 31, 2023 | ($485.49M) | May 16, 2024 |
| FY2023 | Mar 31, 2022 | ($311.20M) | May 18, 2023 |
| FY2022 | Mar 31, 2021 | ($193.17M) | May 19, 2022 |
| FY2021 | Mar 31, 2020 | ($112.30M) | May 20, 2021 |
| FY2019 | Mar 31, 2019 | ($59.77M) | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | ($28.93M) | Jun 28, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $111.12M | May 22, 2025 |
| FY2025 | Mar 31, 2024 | $74.46M | May 22, 2025 |
| FY2024 | Mar 31, 2023 | $146.59M | May 16, 2024 |
| FY2023 | Mar 31, 2022 | $105.95M | May 18, 2023 |
| FY2022 | Mar 31, 2021 | $182.52M | May 19, 2022 |
| FY2021 | Mar 31, 2020 | $59.50M | May 20, 2021 |
| FY2019 | Mar 31, 2019 | $25.70M | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | $17.58M | Jun 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Mar 31, 2020 | $9.80M | May 20, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (3) | May 22, 2025 |
| FY2025 | Mar 31, 2024 | (3) | May 22, 2025 |
| FY2024 | Mar 31, 2023 | (2) | May 16, 2024 |
| FY2023 | Mar 31, 2022 | (2) | May 18, 2023 |
| FY2022 | Mar 31, 2021 | (1) | May 19, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (3) | May 22, 2025 |
| FY2025 | Mar 31, 2024 | (3) | May 22, 2025 |
| FY2024 | Mar 31, 2023 | (2) | May 16, 2024 |
| FY2023 | Mar 31, 2022 | (2) | May 18, 2023 |
| FY2022 | Mar 31, 2021 | (1) | May 19, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 77.09M | May 22, 2025 |
| FY2025 | Mar 31, 2024 | 61.42M | May 22, 2025 |
| FY2024 | Mar 31, 2023 | 56.68M | May 16, 2024 |
| FY2023 | Mar 31, 2022 | 47.34M | May 18, 2023 |
| FY2022 | Mar 31, 2021 | 46.57M | May 19, 2022 |
| FY2021 | Mar 31, 2020 | 36.67M | May 20, 2021 |
| FY2019 | Mar 31, 2019 | 31.66M | Jun 3, 2020 |
| FY2019 | Mar 31, 2018 | 5.01M | Jun 28, 2019 |